Landmark Health Inc. (LHI.US) applies for an IPO in the United States and aims to raise $6 million.

Headquartered in Hong Kong, Excellent Homeopathy (LHI.US), which specializes in homeopathic therapy products, submitted its prospectus to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $6 million in funds through an initial public offering (IPO). The Chinese Hong Kong company intends to issue 1.3 million shares of stock at a price of $4 to $6 per share, with a valuation of $56 million at the midpoint price. According to the prospectus, Excellent Homeopathy's core business is the sale of health care products, including homeopathic remedies (9% of revenue in 2024), homeopathic synergistic therapy products (80%), and flower essence therapy products (4%). These products are mainly purchased from manufacturers and distributed under the company's own brand "LIVING." Additionally, they also offer personal care products (2%, such as mouthwash, toothpaste, shampoo) and water filter products (4%), the latter of which are developed by the company and manufactured by contracted manufacturers. According to Frost & Sullivan data, the company holds a leading market share of 41% in the Hong Kong homeopathic products market in 2023. Founded in 1994, the company had revenues of $8 million in the 12 months ending on September 30, 2024, and plans to list on the Nasdaq under the ticker symbol LHI. Excellent Homeopathy had confidentially submitted its filing on November 1, 2024, with the IPO being managed exclusively by U.S. UP Fintech Holding Ltd. Sponsored ADR Class A as the book-running manager, with specific pricing terms yet to be disclosed.